[팜뉴스=김민건 기자] On the 16th, Pfizer Pharmaceuticals Korea (CEO Dong-wook Oh) released an infographic containing information on pneumococcal serotypes with frequent invasive infections in major countries, divided into adults and children.
Through an infographic, Pfizer highlighted the importance of selecting a vaccine based on a global map, taking into account information on invasive pneumococcal serotypes present mainly in Korea and the distribution dynamics of the serotypes.
Information on the most frequent pneumococcal serotypes in the main countries disclosed by Pfizer Pharmaceuticals Korea
Pneumococci are currently classified into 90 types based on their serotypic characteristics. The serotype that causes invasive pneumococcal infection varies by region, time, use of vaccines, and age. The Korean Society of Pediatrics suggests in its vaccination guidelines: “It is advisable to select and administer a vaccine that is expected to be highly effective in preventing serotypes commonly isolated in Korea.”
Based on the WHO report (Technical Report Series, No. 927, 2005), Pfizer stated that “the number of serotypes included in the vaccine is limited unless there is evidence that the inclusion of additional serotypes will improve the effectiveness in a specific epidemiological context”. “You can’t judge superiority alone,” she explained.
Pfizer said: “In the United States and Canada, 22F is the most common serotype in children and adults. In France, there are differences depending on the country, such as 24F in children and 12F in Israel. It added: “In Korea, serotypes 10A in children and 3 and 19A in adults are serotypes. “Many have been discovered,” she explained.
He continued: “Among the serotypes that can be prevented in children through vaccines, the incidence of 19A and 19F has been high. In particular, 19A has been reported to have a high rate of antibiotic resistance in infected patients, so It has been recommended to vaccinate these serotypes.” reduce the risk of developing serious diseases.” “It’s important to manage them,” she added.
Prevnar 13, developed by Pfizer, treats a total of 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14). It is indicated for the prevention of pneumonia and invasive diseases caused by 18C, 19A, 19F, 23F). This is explained based on this.
Song Chan-woo, vice president of Primary Care Division of Pfizer Korea, said: “Prevenar 13 is a pneumococcal vaccine that has ranked first in sales in Korea for 14 years since its approval. Through this infographic, we will help you understand serotypes that frequently occur in Korea “I hope this serves as an opportunity to confirm the epidemiological importance in choosing a vaccine,” he said.
#common #pneumococcal #serotypes #world #Pfizer #infographic #published
